FDA Calls For Third-Party Auditor To Rectify Actavis Manufacturing Problems
Executive Summary
FDA is recommending that Actavis "promptly initiate" a third-party audit program to oversee the correction of manufacturing discrepancies at the firm's Little Falls, N.J. facility, following the second warning letter for the plant in less than five months